Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.15
+22.4%
$0.06
$0.00
$0.78
$6.28M1.175,514 shs689 shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$4.87
-1.3%
$8.24
$4.36
$94.50
$8.81M0.51144,089 shs57,678 shs
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
$0.69
+8.2%
$0.70
$2.08
$5.16
$5.95M-0.2639,536 shs115,357 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$1.24
-5.0%
$1.46
$0.85
$4.42
$56.45M1.21472,934 shs406,597 shs
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$1.73
$1.38
$3.79
$117.93M1.08126,298 shs141,800 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%0.00%+259.10%+290.58%-37.91%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
+1.65%+2.26%-55.09%-41.14%-93.01%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
+8.21%+4.41%-3.95%-49.93%-84.78%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-1.52%-2.69%-22.62%+26.21%-63.07%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.5342 of 5 stars
3.22.00.00.02.11.71.3
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.0358 of 5 stars
3.74.00.00.01.10.00.0
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.33
Hold$375.007,608.12% Upside
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
0.00
N/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00628.74% Upside
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest REPH, PDSB, NRBO, CLRB, and ADXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/11/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
5/14/2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M1.94N/AN/A($2.06) per share-0.07
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A$8.98 per shareN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/A$1.50 per shareN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.51 per shareN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$75.36M0.00N/AN/A$0.90 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/A

Latest REPH, PDSB, NRBO, CLRB, and ADXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.25-$0.21+$0.04-$0.21N/AN/A
5/13/2025Q1 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$5.10-$3.90+$1.20-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
2.47
2.47
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/A
2.41
2.41
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.29
2.33
2.33
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
2.27
3.24
2.74
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
101.81 million1.72 millionOptionable
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
108.62 million8.53 millionNot Optionable
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2045.71 million41.51 millionOptionable
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
18556.42 million48.41 millionOptionable

Recent News About These Companies

Pharma’s climate change vulnerability and opportunity
Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
Mankind Pharma share price
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
Eversana and Amazon plan generative AI push in pharma
Aurobindo Pharma Ltd.
Sun Pharma reports "information security incident"; isolates impacted IT assets
Societal CDMO Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.15 +0.03 (+22.36%)
As of 03:41 PM Eastern

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$4.86 -0.07 (-1.32%)
Closing price 03:58 PM Eastern
Extended Trading
$4.86 0.00 (-0.10%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

NeuroBo Pharmaceuticals stock logo

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.69 +0.05 (+8.21%)
As of 07/9/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.24 -0.07 (-5.00%)
Closing price 03:58 PM Eastern
Extended Trading
$1.24 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Recro Pharma stock logo

Recro Pharma NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.